# Stéphane Oudard

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephane-oudard/

## Facts

| Field | Value |
| --- | --- |
| Citations | 66,918 |
| Field | Renal cell carcinoma treatment |
| h-index | 102 |
| i10-index | 399 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5059690857 |
| ORCID iD | https://orcid.org/0000-0003-0893-285X |
| Works | 1,254 |

## Researcher papers

- [Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer](https://scholariq.org/papers/docetaxel-plus-prednisone-or-mitoxantrone-plus-prednisone-for-advanced-prostate/)
- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial](https://scholariq.org/papers/safety-and-efficacy-of-sunitinib-for-metastatic-renal-cell-carcinoma-an-expanded/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma](https://scholariq.org/papers/tim-3-expression-on-tumor-infiltrating-pd-1-cd8-t-cells-correlates-with-poor/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.